While there is significant competition, and the market winners are yet to be determined, Guardant Health is well positioned. Guardant has faced skepticism due to its large losses and the ...

Guggenheim restated a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. Sanford C. Bernstein decreased their price objective on Guardant Health from $40. ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange ...

PALO ALTO, Calif., February 07, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately ...

Shares of Guardant Health (GH) have been struggling lately and have lost 6.7% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on GH stock, giving a Buy rating yesterday. Puneet Souda has given his Buy rating due to a combination of factors that ...

On Thursday, Barclays (LON:BARC) began coverage on Guardant Health (NASDAQ:GH) shares, assigning an Overweight rating and setting a price target of $60. The new outlook comes as Guardant Health ...

Guardant Health (GH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated ...